StreetInsider.com News Articles

Qiagen NV (QGEN) Reiterated at Hold by Stifel Post QIAcuity digital PCR Deep-Dive

Tue, 16 Jun 2026 07:24:10 -0400

Stifel analyst Daniel Arias reiterated a Hold rating and $36.00 price target on Qiagen NV (NYSE: QGEN).

The analyst commented, "Qiagen held their third deep-dive session today, meant to highlight QIAcuity digital PCR and several new menu additions to the platform. Much of the info was already familiar to investors, but the session gave a clear read on QGEN's position in the dPCR market and how they intend to take share from incumbents and sustain growth — chiefly through expanding adoption in clinical diagnostics and gene expression. The company unveiled new QIAcuity gene expression assays and confirmed a next-gen "QIAcuity v2"

QIAGEN expands QIAcuity digital PCR portfolio with gene expression tools

Mon, 15 Jun 2026 02:58:52 -0400

QIAGEN N.V. (NYSE: QGEN) announced plans to expand its QIAcuity digital PCR ecosystem with new gene expression capabilities and workflow automation features, according to a company statement.

The Netherlands-based molecular diagnostics company plans to launch QIAcuity Gene Expression Assays in 2026 for human, mouse and rat research applications. The company also intends to introduce the QIAcuity OneStep High Multiplex Probe PCR Kit, which will enable analysis of up to 12 RNA targets in a single reaction.

QIAGEN is expanding its cell and gene therapy quality control portfolio to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

Mon, 15 Jun 2026 01:30:00 -0400

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

TD Cowen notes short interest shifts in life science tools stocks

Wed, 10 Jun 2026 10:50:16 -0400